ARTICLE | Clinical News
GV1001: Phase III start
February 6, 2006 8:00 AM UTC
PHARMX expects to begin next quarter the open-label, international Phase III PrimoVax trial in 520 patients comparing GV1001 against the standard treatment of gemcitabine. The company submitted an app...